



# Acquired Resistance in Lung Cancer Patient Forum

for ALK, ROS1 & EGFR patients & caregivers

Boston | Sept. 6, 2014

Register at [www.cancerGRACE.org](http://www.cancerGRACE.org)

8 – 9 a.m.	Registration/ Breakfast
9 – 10:40 a.m.	<p><b>Welcome</b> <i>Dr. Howard (Jack) West, Swedish Cancer Institute/President of GRACE</i></p> <p><b>What is Acquired Resistance &amp; Why Does It Occur?</b> <i>Dr. Gregory J. Riely, Memorial Sloan Kettering Cancer Center</i></p> <p><b>Continuing Current Systemic Therapy Without Change, Adding Local or Systemic Therapy, or Switching to New Options: Choosing Among Alternatives</b> <i>Dr. Jared Weiss, Univ. of North Carolina/Vice President of GRACE</i></p> <p><b>Repeat Biopsies &amp; the Potential Value of Biologically Informed Acquired Resistance Therapy</b> <i>Dr. Lecia V. Sequist, Massachusetts General Hospital</i></p> <p>Q&amp;A - Drs. Riely, Weiss &amp; Sequist; moderated by Dr. West</p>
10:40 – 11 a.m.	Break
11 a.m. – 12:10 p.m.	<p><b>Clinical Trial Design &amp; Development of Highly Targeted Agents in the Molecular Oncology Era</b> <i>Dr. Gideon M. Blumenthal, U.S. Food &amp; Drug Administration</i></p> <p><b>The Role of Off Target Therapies for Targeted Populations</b> <i>Dr. Nathan Pennell, Cleveland Clinic</i></p> <p>Q&amp;A - Drs. Blumenthal and Pennell; moderated by Dr. West</p>
12:10 – 1 p.m.	Lunch

<p>1 – 2:05 p.m.</p>	<p><b>**ALK/ROS1 Rearrangement Track**</b></p> <p>Introductions - <i>Dr. Jack West</i></p> <p><b>Mechanisms of ALK Resistance &amp; Implications for Treatment</b> <i>Dr. Robert C. Doebele, University of Colorado at Denver</i></p> <p><b>Current &amp; Emerging Approaches to Acquired Resistance for ALK/ROS1</b> <i>Dr. Alice T. Shaw, Massachusetts General Hospital</i></p> <p>Q&amp;A - <i>Drs. Doebele &amp; Shaw; moderated by "CraigInPA," online patient advocate</i></p>
<p>1 – 2:05 p.m.</p>	<p><b>**EGFR Mutation Track**</b></p> <p>Introductions - <i>Dr. Jared Weiss</i></p> <p><b>Novel EGFR Inhibitors in the Setting of Acquired Resistance</b> <i>Dr. Pasi A. Jänne, Dana-Farber Cancer Institute</i></p> <p><b>Combinations for Treating EGFR Acquired Resistance</b> <i>Dr. Melissa L. Johnson, Robert H. Lurie Comprehensive Cancer Center</i></p> <p>Q&amp;A - <i>Drs. Janne &amp; Johnson; moderated by Dr. Weiss</i></p>
<p>2:05 – 2:20 p.m.</p>	<p>Break</p>
<p>2:20 – 3:30 p.m.</p>	<p><b>Leveraging Patient Engagement &amp; the Role of Advocacy</b> <i>Bonnie J. Addario, Addario Lung Cancer Foundation</i></p> <p><b>The Expanding Role of Patient Self-Education &amp; Online Communities in Molecularly Defined Subgroups</b> <i>"CraigInPA," online patient advocate</i></p> <p><b>Cost &amp; Access of Molecularly Targeted Therapies as Barriers to Optimal Care</b> <i>Dr. Howard (Jack) West</i></p> <p>Q&amp;A - <i>Ms. Addario, CraigInPA &amp; Dr. West</i></p> <p>Close - <i>Dr. Jack West</i></p>